PTC Therapeutics, Inc.

PTC Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for children and adults living with rare disorders. Its marketed products include Translarna and Emflaza for Duchenne muscular dystrophy, Upstaza (marketed as Kebilidi in the United States) for AADC deficiency, Tegsedi and Waylivra for rare diseases, and Evrysdi for spinal muscular atrophy. The company also has a development pipeline including Sepiapterin for phenylketonuria, PTC518 for Huntington's disease, and vatiquinone for Friedreich's ataxia. PTC Therapeutics distributes its products through third-party distributors and collaborates with organizations such as F. Hoffman-La Roche Ltd., the SMA Foundation, and Novartis Pharmaceuticals Corporation.

PTC Therapeutics, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol PTCT. The company trades in United States Dollars (USD), as it is headquartered in the United States and its primary listing is on a US exchange.

PTC Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on developing and commercializing therapies for rare disorders, which is a specialized area of biotechnology that addresses unmet medical needs for small patient populations.

PTC Therapeutics, Inc. is headquartered in Warren, New Jersey, United States. The company serves patients in the United States and globally, with a particular focus on rare disorders. Its products are distributed through third-party distributors, and it has collaborations with international partners such as F. Hoffman-La Roche Ltd., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd., indicating a global reach.

PTC Therapeutics has a portfolio of approved products and a robust pipeline. Approved products include Translarna and Emflaza for Duchenne muscular dystrophy, Upstaza (branded as Kebilidi in the US) for AADC deficiency, Tegsedi and Waylivra for rare diseases, and Evrysdi for spinal muscular atrophy. The pipeline features Sepiapterin for phenylketonuria, PTC518 for Huntington's disease, and vatiquinone for Friedreich's ataxia. Additionally, the company is developing inflammation and ferroptosis platforms. PTC Therapeutics also has a license and collaboration agreement with Novartis Pharmaceuticals Corporation to advance the PTC518 Huntington's disease program.